OPRX - OptimizeRx Corporation
| Previous Close | 10.18 |
| Open | 10.20 |
| Bid | 8.65 x 800 |
| Ask | 13.58 x 900 |
| Day's Range | 10.12 - 10.23 |
| 52 Week Range | 8.63 - 17.24 |
| Volume | 20,289 |
| Avg. Volume | 110,377 |
| Market Cap | 148.042M |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.10 |
| Earnings Date | Nov 04, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.33 |
- Insider Monkey
Hedge Funds Have Never Been More Bullish On OptimizeRx Corporation (OPRX)
Is OptimizeRx Corporation (NASDAQ:OPRX) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
- Simply Wall St.
We're Excited To See How OptimizeRx (NASDAQ:OPRX) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
OptimizeRx Sales Pipeline Up 79% to $84 Million in 2019; Company Reiterates Strong Q4 and 2020 Outlook
OptimizeRx Corp. (OPRX), a leading provider of digital health solutions for pharmaceutical companies, payers, medtech and medical associations, reported its sales pipeline, which is comprised of outstanding request for proposals (RFPs) submitted, has increased 79% to $84 million in 2019 as compared to last year. The company’s RFPs have historically realized a 35%-50% close rate. “Our sales pipeline growth is being driven by an accelerated migration to digital solutions by pharma, along with a greater focus on patient experience,” noted Stephen Silvestro, chief commercial officer of OptimizeRx.
- Thomson Reuters StreetEvents
Edited Transcript of OPRX earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 OPTIMIZERx Corp Earnings Call
- GlobeNewswire
OptimizeRx Reports Third Quarter 2019 Results
ROCHESTER, Mich., Nov. 05, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health solutions for pharmaceutical companies, payers, medtech and medical.
- Simply Wall St.
Does OptimizeRx Corporation's (NASDAQ:OPRX) CEO Salary Reflect Performance?
Will Febbo became the CEO of OptimizeRx Corporation (NASDAQ:OPRX) in 2016. First, this article will compare CEO...
- GlobeNewswire
OptimizeRx Launches Newly Integrated Platform to Improve Outcomes
OptimizeRx Corp. (OPRX), a leading provider of digital health solutions for pharmaceutical companies, payers, medtech and medical associations, has integrated its core set of solutions into a single platform to more effectively address the need for greater patient-provider-pharma-payer collaboration and improvement in medication affordability and adherence. OptimizeRx recently announced the acquisition of the digital therapeutics SaaS provider, RMDY Health, as well as an exclusive three-year partnership with NewCrop, a provider of integrated electronic prescribing software. “Following our latest acquisitions where we entered the additional payer and medical device market, we have now brought together all of our existing and newest offerings onto a single platform with touchpoints throughout the care journey,” said Steve Silvestro, chief commercial officer at OptimizeRx.
- GlobeNewswire
OptimizeRx to Participate at Investor Conferences in November
ROCHESTER, Mich., Oct. 24, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health solutions for pharmaceutical companies, payers, medtech companies and.
- GlobeNewswire
OptimizeRx Sets Third Quarter 2019 Conference Call for Tuesday, November 5, 2019 at 4:30 p.m. ET
ROCHESTER, Mich., Oct. 22, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health solutions for payers, medtech companies, medical associations and the.
- GlobeNewswire
OptimizeRx Sponsors WOMEN at HLTH Program at the 2019 HLTH Conference
OptimizeRx Corp. (OPRX), a leading platform for digital health messaging in the pharmaceutical industry, is sponsoring the WOMEN at HLTH program at HLTH 2019, the nation’s largest conference focused on health innovation. HLTH is a one-of-a-kind ecosystem event for the health industry, bringing together more than 5,000 senior leaders to address the most pressing problems facing healthcare today. WOMEN at HLTH is a series of activities at HLTH focused on advancing and empowering women.
- Thomson Reuters StreetEvents
Edited Transcript of OPRX earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 OPTIMIZERx Corp Earnings Call
- GlobeNewswire
OptimizeRx Signs Exclusive Agreement with NewCrop to Offer Digital Health Messages and Create a Health Tech Innovation Lab for Life Sciences
OptimizeRx Corp. (OPRX), a leading provider of digital health solutions for payers, medtech companies, medical associations and the pharmaceutical industry, has secured a three-year exclusive partnership with NewCrop, a provider of integrated electronic prescribing software, to deliver real-time digital health messages to NewCrop’s e-prescribing network of more than 65,000 healthcare professionals. The agreement builds upon a long standing, profitable relationship between the two partners, and solidifies OptimizeRx as the largest digital platform connecting life sciences to the point-of-care.
- GlobeNewswire
OptimizeRx Invited to Host Plenary Sessions at Digital Pharma East on September 17-20, 2019
OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, will host two plenary sessions at the 13th Annual Digital Pharma East conference being held at the Pennsylvania Convention Center in Philadelphia on September 17-20, 2019. Bringing together more than 1,000 participants, this conference will feature latest case studies and senior-level discussions with pharma companies, health systems, physicians, health-tech companies, startups and non-traditional healthcare companies involved in digital health. The first plenary session, “Success in Today’s Evolving Pharma Marketing Landscape,” will be hosted by Steve Silvestro, chief commercial officer of OptimizeRx, at 11:00 a.m. Eastern time on September 17.
- Zacks
Zacks.com featured highlights include: Digital Turbine, Perion, Controladora Vuela, OptimizeRx and Eldorado Gold
Zacks.com featured highlights include: Digital Turbine, Perion, Controladora Vuela, OptimizeRx and Eldorado Gold
- Zacks
5 Breakout Stocks for Explosive Returns
This method involved zeroing in on those stocks whose prices are varying within a narrow band.
- GlobeNewswire
OptimizeRx to Acquire Digital Therapeutics SaaS Platform Provider, RMDY Health
OptimizeRx Corp. (OPRX) to acquire RMDY Health, a multipurpose digital therapeutics SaaS platform, for $16 million in cash and equity. The RMDY Health platform is used by pharma, payers, MedTech companies and medical associations nationwide.
- Simply Wall St.
Should You Be Holding OptimizeRx Corporation (NASDAQ:OPRX)?
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...
- GlobeNewswire
OptimizeRx to Participate at Lake Street Annual Best Ideas Growth Conference on September 12, 2019
OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, has been invited to participate in the Lake Street Capital Markets 3rd Annual Best Ideas Growth (BIG3) Conference being held on September 12, 2019 at the Parker New York. The company’s digital health network is expanding into the acute care market after reaching more than half of the ambulatory patient market in the U.S. The event is for institutional clients of Lake Street and is by invitation only.
- Simply Wall St.
Imagine Holding OptimizeRx (NASDAQ:OPRX) Shares While The Price Zoomed 331% Higher
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. You won't get...
- GlobeNewswire
OptimizeRx Reports Record Second Quarter 2019 Results; Total Revenue Up 37% to $7.0 Million, Net Income up 45% to $407,000 or $0.03 per Diluted Share
ROCHESTER, Mich., Aug. 07, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, reported results for the.
- Zacks
Has OptimizeRx (OPRX) Outpaced Other Computer and Technology Stocks This Year?
Is (OPRX) Outperforming Other Computer and Technology Stocks This Year?
- Zacks
OptimizeRx (OPRX) to Report Q2 Earnings: What's in Store?
OptimizeRx's (OPRX) second-quarter 2019 results are likely to benefit from increased sales of core financial and brand messaging products.
- Zacks
OptimizeRx (OPRX) Gains As Market Dips: What You Should Know
OptimizeRx (OPRX) closed the most recent trading day at $15.09, moving +0.8% from the previous trading session.
- Zacks
OptimizeRx (OPRX) Reports Next Week: Wall Street Expects Earnings Growth
OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
